PT - JOURNAL ARTICLE AU - Santos Guedes de Sa, Keyla AU - Silva, Julio AU - Bayarri-Olmos, Rafael AU - Brinda, Ryan AU - Alec Rath Constable, Robert AU - Colom Diaz, Patricia A. AU - Kwon, Dong-il AU - Rodrigues, Gisele AU - Wenxue, Li AU - Baker, Christopher AU - Bhattacharjee, Bornali AU - Wood, Jamie AU - Tabacof, Laura AU - Liu, Yansheng AU - Putrino, David AU - Horvath, Tamas L. AU - Iwasaki, Akiko TI - A causal link between autoantibodies and neurological symptoms in long COVID AID - 10.1101/2024.06.18.24309100 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.18.24309100 4099 - http://medrxiv.org/content/early/2024/06/19/2024.06.18.24309100.short 4100 - http://medrxiv.org/content/early/2024/06/19/2024.06.18.24309100.full AB - Acute SARS-CoV-2 infection triggers the generation of diverse and functional autoantibodies (AABs), even after mild cases. Persistently elevated autoantibodies have been found in some individuals with long COVID (LC). Using a >21,000 human protein array, we identified diverse AAB targets in LC patients that correlated with their symptoms. Elevated AABs to proteins in the nervous system were found in LC patients with neurocognitive and neurological symptoms. Purified Immunoglobulin G (IgG) samples from these individuals reacted with human pons tissue and were cross-reactive with mouse sciatic nerves, spinal cord, and meninges. Antibody reactivity to sciatic nerves and meninges correlated with patient-reported headache and disorientation. Passive transfer of IgG from patients to mice led to increased sensitivity and pain, mirroring patient-reported symptoms. Similarly, mice injected with IgG showed loss of balance and coordination, reflecting donor-reported dizziness. Our findings suggest that targeting AABs could benefit some LC patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Else Kroner Fresenius Prize for Medical Research 2023, grants from the National Institute of Allergy and Infectious Diseases (R01AI157488 to A.I.), RTW Foundation (D.P.), the Howard Hughes Medical Institute Collaborative COVID-19 Initiative (A.I.), Howard Hughes Medical Institute Emerging Pathogens Initiative (A.I.), and the Howard Hughes Medical Institute (A.I.). Steve and Alexandra Cohen Foundation (D.P. and J.W.), Nash Family Foundation (D.P. and J.W.) and Polybio Research Foundation (D.P. and J.W.). K.S.G.S. receive research support from Pew Latin American Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Mount Sinai Program for the Protection of Human Subjects (IRB 20-01758) and Yale Institutional Review Board (IRB 2000029451 for MY-LC; IRB 2000028924 for enrolment of pre-vaccinated Healthy Controls). Informed consent was obtained from all enrolled participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors